DIRS.INFO The most relevant business & tech news

☆ Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
▼ + stars: | 2024-10-02 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +2 min

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. The Food and Drug Administration cleared the investigational new drug application for a phase 1/2 clinical trial of an experimental drug candidate known as REC-1245. The company said the potential market for this treatment could be more than 100,000 patients in the U.S. and European Union. The trial will evaluate the safety and tolerability of REC-1245 and will begin in the fourth quarter of this year. "It's the first program that really is leveraging many of these new tools that we've built in one unit."

Persons: Chris Gibson, Gibson Organizations: Pharmaceuticals, CNBC, Drug Administration, Union, REC Locations: U.S

☆ Qureight uses AI to help speed up drug development. Check out the 11-slide pitch deck it used to raise $8.5 million.
▼ + stars: | 2024-04-16 | by ( Riddhi Kanetkar | ) www.businessinsider.com time to read: +2 min

British techbio startup Qureight has secured $8.5 million in an oversubscribed Series A round. Launched in 2018, Qureight wants to simplify how pharma companies deal with the complex datasets often used during clinical trials. "For example, we can start to structure images of lungs using AI," said cofounder and CEO Muhunthan Thillai. The startup primarily works with pharmaceutical companies, including heavyweights such as AstraZeneca, as well as hospitals and clinical research organizations. Check out the 11-slide pitch deck used to secure the fresh funding.

Persons: Qureight, Muhunthan Thillai, Thillai, Hargreave Hale Organizations: pharma, Business, AstraZeneca, Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Playfair, Fund, Cambridge Angels Locations: Cambridge, Meltwind

☆ Top Wall Street analysts pick these stocks for solid returns
▼ + stars: | 2024-01-21 | by ( Tipranks.Com Staff | ) www.cnbc.com time to read: +5 min

Nonetheless, analysts remain focused on the bigger picture and are bullish on stocks that offer attractive long-term growth prospects. Investors can weigh the recommendations of Wall Street's top analysts as they pick out the best names to add to their portfolios. With that in mind, here are three stocks favored by the Street's top pros, according to TipRanks, a platform that ranks analysts based on their past performance. The stock generated stellar returns last year due to the robust demand for the company's graphics processing units in generative AI. He thinks that the health-care business features among the top three verticals of the company's data center segment.

Persons: Wall, Brad Erickson, Erickson, TipRanks, Brian Pitz, Pitz, Harlan Sur, Kimberly Powell Organizations: RBC Capital, Web Services, BMO Capital, TAM, Nvidia, JPMorgan, Pharmaceuticals Locations: U.S, Europe, DoorDash's U.S, Sur

☆ Drug discovery and 'techbio': What Europe's health startup investors are betting on in 2023
▼ + stars: | 2023-06-24 | by ( Riddhi Kanetkar | ) www.businessinsider.com time to read: +4 min

They named drug discovery and the emerging 'techbio' sector as areas of interest. COVID-19 fueled huge interest in health-tech startups, with VCs pouring a record $25.1 billion into health and biotech startups in 2021. Startups in the space are bringing new applications of tech to fields such as drug discovery, bioengineering, and patient care. VCs are still betting on drug discoveryEven though funding into drug discovery startups has significantly stalled this year, at just $126 million, startup valuations have picked up since 2022. Health-tech VCs won't splurge cashWhile COVID-19 did give healthtech startups a chance at the spotlight, they were still overshadowed by their counterparts in fintech and software-as-a-service.

Persons: techbio, healthtech Organizations: Morning, VCs, pharma, Big Pharma Locations: fintech, Munich, Germany, Europe

Search resuls for: "techbio"

4 mentions found